Your browser doesn't support javascript.
loading
Safety and immunogenicity of live-attenuated Japanese encephalitis SA 14-14-2 vaccine co-administered with measles vaccine in 9-month-old infants in Sri Lanka.
Wijesinghe, Pushpa Ranjan; Abeysinghe, M R Nihal; Yoksan, Sutee; Yao, Yafu; Zhou, Benli; Zhang, Lei; Yaich, Mansour; Neuzil, Kathleen M; Victor, John C.
Afiliação
  • Wijesinghe PR; Epidemiological Unit, Ministry Of Healthcare and Nutrition, Colombo, Sri Lanka.
  • Abeysinghe MR; Epidemiological Unit, Ministry Of Healthcare and Nutrition, Colombo, Sri Lanka.
  • Yoksan S; Mahidol University, Bangkok, Thailand.
  • Yao Y; Chengdu Institute of Biological Products, Chengdu, China.
  • Zhou B; Chengdu Institute of Biological Products, Chengdu, China.
  • Zhang L; Chengdu Institute of Biological Products, Chengdu, China.
  • Yaich M; PATH, Ferney Voltaire, France.
  • Neuzil KM; PATH, Seattle, WA, USA.
  • Victor JC; PATH, Seattle, WA, USA. Electronic address: cvictor@path.org.
Vaccine ; 32(37): 4751-7, 2014 Aug 20.
Article em En | MEDLINE | ID: mdl-24951871
ABSTRACT

INTRODUCTION:

To facilitate introduction of live attenuated SA 14-14-2 Japanese encephalitis vaccine (LJEV) into the National Immunization Programme of Sri Lanka, we evaluated the safety and immunogenicity of co-administration of LJEV and measles vaccine at 9 months of age. Serum immune responses were evaluated post-vaccination on days 28, 180, and 365 using JE neutralization test and anti-measles IgG ELISA.

RESULTS:

278 infants received one dose of LJEV and measles vaccine. Of these, 257 were eligible for the per-protocol analysis. On Day 0, 14 infants (5.5%) were seropositive for JE, but none were seropositive for measles. At Day 28, seropositivity rates were 90.7% (95% CI, 86.4-93.9%) for JE and 84.8% (95% CI, 79.8-89.0%) for measles. The geometric mean titer for JE neutralizing antibodies was 111 (95% CI, 90-135), and the geometric mean concentration (GMC) for anti-measles IgG was 375 mI U/mL (95% CI, 351-400 mI U/mL). Over the next year, JE neutralizing antibody responses declined only slightly, with seropositivity at 87.4% (95% CI, 82.6-91.2%) at Day 365. In contrast, measles antibody levels continued to increase over time. Seropositivity for anti-measles IgG reached 97.2% (95% CI, 94.4-98.9%) at Day 365, and the GMC rose to 1202 mI U/mL (95% CI, 1077-1341 mI U/mL). Co-administration of LJEV and measles vaccine was also safe. Most adverse reactions were mild, and no serious adverse events were related to study vaccinations.

CONCLUSION:

The safety and immunogenicity of LJEV co-administered with measles vaccine in Sri Lankan infants is similar to that seen in other populations, and our results support use of LJEV at 9 months of age. Live SA 14-14-2 vaccine is now prequalified by the WHO for use in infants in Asia, and other countries may wish to introduce LJEV to combat this devastating disease.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Vacina contra Sarampo / Esquemas de Imunização / Encefalite Japonesa / Vacinas contra Encefalite Japonesa Limite: Female / Humans / Infant / Male País como assunto: Asia Idioma: En Ano de publicação: 2014 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Vacina contra Sarampo / Esquemas de Imunização / Encefalite Japonesa / Vacinas contra Encefalite Japonesa Limite: Female / Humans / Infant / Male País como assunto: Asia Idioma: En Ano de publicação: 2014 Tipo de documento: Article